Trials / Completed
CompletedNCT04252742
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 512 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erenumab | 140 mg, 2 consecutive injections of 70 mg |
| DRUG | Placebo | 2 consecutive injections |
Timeline
- Start date
- 2020-09-15
- Primary completion
- 2023-10-26
- Completion
- 2023-10-26
- First posted
- 2020-02-05
- Last updated
- 2026-03-31
- Results posted
- 2024-08-30
Locations
91 sites across 9 countries: United States, Bulgaria, Czechia, Hungary, Italy, Poland, Portugal, Romania, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04252742. Inclusion in this directory is not an endorsement.